The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recognized with official accreditation for CAR T-cell therapy from the Foundation for the Accreditation of Cellular Therapy, an international accrediting body. The program was also ranked among the top adult bone marrow transplant programs in the U.S. for a third year.
Roswell Park has opened the Marie E. Bogner Center for Nursing Excellence. The 5,126 square-foot space houses smart classrooms, flexible skills learning areas, and a lactation room.
Yale Cancer Center’s Annual Conclave, held on Jan. 5, recognized the scientific and clinical accomplishments of Smilow Cancer Hospital and Yale Cancer Center over the past year.
Rachel Abbott was named chief scientific officer of Pan Cancer T, a biotech spin-off from Erasmus MC focused on the discovery and development of next-generation TCR-T therapies against solid tumors.
The American Cancer Society’s Cancer Facts & Figures 2023, released last week, reports that the five-year survival rate for pancreatic cancer is now 12%, an increase of one percentage point from last year.
A four-drug chemotherapy regimen provided longer overall survival than a two-drug combination in a phase III clinical trial for metastatic pancreatic ductal adenocarcinoma.
According to a large study led by researchers at the American Cancer Society, the risk of suicide for individuals diagnosed with cancer in the United States is 26% higher, compared with the general population.
A MUSC Hollings Cancer Center pilot trial evaluating brief tele-cognitive behavioral therapy developed specifically for head and neck cancer survivors with body-image distress showed promising results.
Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival time for patients with advanced biliary tract cancers, but it may provide a benefit for subsets of patients with locally-advanced disease or gallbladder adenocarcinoma.
FDA granted accelerated approval to Tukysa (tucatinib) in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive, unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
